Silvia Bellini

TL;DR: The results show that a cellular, tissue-engineered airway with mechanical properties that allow normal functioning, and which is free from the risks of rejection, is produced, suggesting that autologous cells combined with appropriate biomaterials might provide successful treatment for patients with serious clinical disorders.

TL;DR: These observations provide the first demonstration that CD105(+)/CD31(-)/KDR(-) cells are able not only to differentiate in vivo towards the myogenic lineage, but also to contribute to the muscle regenerative process.

TL;DR: The present results indicate that autologous myoblast-homologous acellular muscle matrix constructs are a promising tool for body-wall defect repair, and studies are under way to identify strategies able to improve and maintain the structural and functional integrity of implants for longer periods.

TL;DR: There was no development of anti-pig leukocyte antigen antibodies or increase in both IgM and IgG content in mice implanted with bioengineered tracheas and this method holds great promise for the future of tissue-engineered airway replacement.

TL;DR: It is concluded that cell-matrix constructs could represent a promising approach to the repair of muscle defects, because they are repopulated in vivo by skeletal muscle cells and nervous elements and maintain their structural integrity over the long term.